The therapeutic armamentarium for the treatment of patients with lymphoproliferative diseases has grown considerably over the most recent years, including a large use of new immunotherapeutic agents. As a consequence, the epidemiology of infectious complications in this group of patients is poorly documented, and even more importantly, the potential benefit of antimicrobial prophylaxis remains a matter of debate when considering the harmful effect from the emergence of multidrug resistant pathogens. The present position paper is addressed to all hematologists treating patients affected by lymphoproliferative malignancies with the aim to provide clinicians with a useful tool for the prevention of bacterial, fungal and viral infections.
Considerations on antimicrobial prophylaxis in patients with lymphoproliferative diseases: A SEIFEM group position paper / Busca, A.; Cattaneo, C.; De Carolis, E.; Nadali, G.; Offidani, M.; Picardi, M.; Candoni, A.; Ceresoli, E.; Criscuolo, M.; Delia, M.; Della Pepa, R.; Del Principe, I.; Fanci, R. R.; Farina, F.; Fracchiolla, N.; Giordano, C.; Malagola, M.; Marchesi, F.; Piedimonte, M.; Prezioso, L.; Quinto, A. M.; Spolzino, A.; Tisi, M. C.; Trastulli, F.; Trecarichi, E. M.; Zappasodi, P.; Tumbarello, M.; Pagano, L.. - In: CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. - ISSN 1040-8428. - 158:(2021), p. 103203. [10.1016/j.critrevonc.2020.103203]
Considerations on antimicrobial prophylaxis in patients with lymphoproliferative diseases: A SEIFEM group position paper
Picardi M.;Della Pepa R.;Giordano C.;Trastulli F.;
2021
Abstract
The therapeutic armamentarium for the treatment of patients with lymphoproliferative diseases has grown considerably over the most recent years, including a large use of new immunotherapeutic agents. As a consequence, the epidemiology of infectious complications in this group of patients is poorly documented, and even more importantly, the potential benefit of antimicrobial prophylaxis remains a matter of debate when considering the harmful effect from the emergence of multidrug resistant pathogens. The present position paper is addressed to all hematologists treating patients affected by lymphoproliferative malignancies with the aim to provide clinicians with a useful tool for the prevention of bacterial, fungal and viral infections.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
